Associated Papers
Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer.
Weddle CJ et al.
Npj Precision Oncology, 2025
40000798 (PubMed )
Supplement: 41698_2025_837_MOESM3_ESM.xlsx › BC3
Clinical significance of genetic variation in hypertrophic cardiomyopathy: comparison of computational tools to prioritize missense variants.
Barbosa P et al.
Frontiers in Cardiovascular Medicine, 2022
36061567 (PubMed )
Supplement: Table_1.XLSX › Table_S3
Mutation in δ-Sg Gene in Familial Dilated Cardiomyopathy.
Asadi M et al.
Advanced Biomedical Research, 2017
Dilated cardiomyopathy mutations in δ-sarcoglycan exert a dominant-negative effect on cardiac myocyte mechanical stability.
Campbell MD et al.
American Journal of Physiology. Heart and Circulatory Physiology, 2016
A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy.
Kärkkäinen S et al.
Journal of Molecular Medicine (berlin, Germany), 2003
Mutational analysis of the beta- and delta-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy.
Sylvius N et al.
American Journal of Medical Genetics. Part A, 2003
Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy.
Tsubata S et al.
The Journal of Clinical Investigation, 2000
Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein.
Nigro V et al.
Human Molecular Genetics, 1996
Select a paper to view details